Retard form of pharmaceuticals with insoluble porous diffusion coatings

US4578264A · kind A · utility

Assignee

• Boehringer Ingelheim GmbH · DE

Inventors

• Herbert Stricker · Ingelheim am Rhein, DE
• Bernhard Freund · Gau-Algesheim, DE
• Heribert Harwalik · Ingelheim am Rhein, DE
• Karl L. Rominger · Ingelheim am Rhein, DE
• Siegfried Darda · Ingelheim am Rhein, DE
• Volkmar Haselbarth · Ingelheim am Rhein, DE
• Dietrich Arndts · Appenheim, DE
• Wolf-Dietrich Bechtel · Appenheim, DE
• Gerhard Bozler · Biberach, DE
• Rolf-Stefan Brickl
• Peter Gruber · Bottmingen, CH

Key dates

• Filing date: Apr 27, 1984
• Grant date: Mar 25, 1986
• Expiry date: Apr 27, 2004

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K9/4808
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention relates to a pharmaceutical dosage unit composition consisting essentially of a gelatin capsule containing (1) a disintegrating core comprising clonidine, said disintegrating core having a readily water-soluble coating, and (2) a plurality of non-disintegrating cores comprising clonidine, said non-disintegrating cores having a coating consisting of from 20 to 90 percent by weight of a water-insoluble film former and from 10 to 80 percent by weight of a water-soluble polymer, the diameter of each of the disintegrating and non-disintegrating cores being at least about 5 mm.